BIOCERES CROP SOLU Overview
Bioceres Crop Solutions is an Argentine-rooted agricultural inputs and biotechnology company. It sells biologicals (inoculants, bio-protection seed treatments), adjuvants, micro-beaded fertilizers and third-party crop protection products, mainly through its 80%-owned subsidiary Rizobacter. It also holds licensed rights to the HB4® drought-tolerance trait for wheat and soybean. Between 2019 and 2024 the company used SPAC capital, the 2022 all-stock Marrone Bio merger and secured note financing to build what it called a "regenerative" crop-productivity platform. Revenue peaked at US$464.8M in FY2024. Since then the company has gone through an Argentine demand shock, a covenant breach, loss of control of its parent group, and the foreclosure of its U.S./European biologicals arm (Pro Farm). It also carries a going-concern qualification and a Nasdaq bid-price deficiency. Today BIOX is a sub-US$30M market-cap, highly levered (net financial debt US$213.6M), Argentina-centric inputs business. It is executing a cost-led turnaround while litigating with its noteholders.
What the company does
Bioceres develops, manufactures and sells crop-productivity inputs for row-crop agriculture (soybean, wheat, corn and others). Its continuing operations, after the PFG foreclosure, are concentrated in Argentina through Rizobacter Argentina S.A. (Pergamino). Rizobacter makes and sells three main things:
Inoculants: biological nitrogen-fixation products for legumes, plus related biological seed treatments.
Adjuvants: spray additives that improve the performance of agrochemicals.
Micro-beaded / micro-granulated fertilizers: produced at the Synertech Industrias joint-venture plant with De Sangosse.
Rizobacter also distributes third-party crop protection products. The Seed and Integrated Products segment, run historically through Bioceres Semillas, covered HB4 wheat and soybean seed sales, grain integration programs and "seed treatment packs." After a two-year reconfiguration it is now moving to an asset-light HB4 trait-licensing model (Form 20-F FY2025; FY2026 earnings release).
Company's own description (latest filings)
The FY2026 earnings release (September 14, 2026) describes the company as a leader in the development and commercialization of productivity solutions that regenerate agricultural ecosystems and make crops more resilient to climate change. It adds that its solutions create economic incentives for farmers to adopt environmentally friendlier practices. It cites a biotech platform with patented technologies for seeds and microbial inputs, plus next-generation Crop Nutrition and Protection solutions (paraphrased from the "About" boilerplate).
Business and revenue model
| Revenue type | Description | Indicative weight (FY2026, continuing) |
|---|---|---|
| Proprietary product sales | Adjuvants, inoculants, micro-beaded fertilizers, biological seed treatments sold to distributors, cooperatives and growers | Majority of revenue. Precise split n/d. |
| Third-party product resale | Third-party crop protection products sold mainly in Argentina | Declining. Cited as a driver of lower Crop Protection revenue in FY2026. |
| Seed and grain integration | HB4 seed and grain programs | Being wound down. Seeds/HB4 caused about half of the FY2026 revenue decline. |
| Licensing / royalties | HB4 trait licensing to third-party seed companies; Syngenta agreement for biological seed treatments | Growing in strategic importance. Syngenta contribution fell in FY2026. |
| Strategic up-front payments | Syngenta up-front payment recognized over time (US$33M recognized in FY2023, about US$17M in FY2024, per FY2024 earnings call) | Lumpy; it inflated FY2023–FY2024 Crop Nutrition margins |
Subscription or SaaS revenue is n/d; the company has no material subscription model.
Value-chain position
Bioceres sits between technology discovery (CONICET/UNL-origin HB4 science; microbial strain libraries) and the farm gate. It combines its own manufacturing (Pergamino plants; Synertech JV) with distribution through Argentine agro-retail channels and international subsidiaries and distributors. Its key advantages are formulation know-how and channel reach in Argentina. Its key weaknesses are limited scale outside Argentina after losing Pro Farm, and dependence on Argentine farmer credit.
Customers and end-markets
Customer types: Agro-input distributors and retailers, cooperatives, large growers, seed companies (HB4 licensees and seed-treatment packs) and multinational partners (Syngenta).
End-markets: Soybean, wheat, corn and other row crops in Argentina (dominant), Brazil, the rest of Latin America, North America (heavily reduced after PFG) and EMEA.
Independent characterization
BIOX is now a distressed, single-country-dependent specialty-inputs company with a residual biotech option (HB4). Its core franchises are still profitable at the gross level: FY2026 continuing gross margin was 34.8% and 1H FY2026 consolidated gross margin was about 40% (CEO letter, March 2026). Equity value, however, is dominated by the capital structure. Secured notes carry 15–19% coupons, and their acceleration is disputed. Total financial debt of US$225.9M sits against FY2026 Adjusted EBITDA of US$25.5M. The investment case has shifted from "growth biotech" to "restructuring and recovery."
Strategy
Stated strategy themes (latest filings and letters, paraphrased)
-
Focus on core capabilities. Concentrate on the continuing Argentine-anchored business and its "core technology platforms." The March 2026 CEO letter says continuing operations are centered on Argentina.
-
Cost and operating discipline. Lower the fixed and variable cost base. FY2026 SG&A fell US$22.5M (−24%).
-
Portfolio and channel rationalization. After an external strategic assessment completed in 2026, management plans to rationalize the portfolio and go-to-market channels, revisit commercial policies and strategic relationships, and tie R&D (which the company calls "R&D&R") to defined financial objectives (FY2026 release).
-
Asset-light seeds. Complete the shift from own-channel HB4 seed sales to trait licensing (20-F FY2025; FY2026 release).
-
Capital structure. Resolve the Pro Farm and noteholder situation through negotiation or litigation and "develop a sustainable capital structure" (CEO letter, March 2026). Continue liability management at Rizobacter (bank reprofiling) and a voluntary maturity extension on Argentine local bonds (obligaciones negociables).
-
Three-year plan. The board directed management to build a comprehensive three-year financial plan for the business excluding Pro Farm, focused on profitability and cash flow (CEO letter, March 2026). The plan itself is not public.
Initiatives register (last 24 months)
| Date | Initiative | Type | Detail / target | Status |
|---|---|---|---|---|
| FY2025 | Seed business reconfiguration (HB4 licensing) | Business model transition | Stop own-brand HB4 seed sales | Substantially completed (FY2026 release) |
| May 2025 | HB4 wheat license made exclusive worldwide | IP / licensing | Amendment to the March 2022 license | Effective, but terminable after the June 2025 change of control |
| Jun 2025 | Note amendment and board refresh | Liability management | Covenant reset to 5.0x; maturity extended to Aug 2027 | Superseded by the acceleration dispute |
| FY2026 | Cost reduction program | Cost | Operating expenses −20% (US$103.2M to US$82.3M) | Achieved |
| FY2026 | Rizobacter bank debt reprofiling | Liability management | Agreements covering "a substantial portion" of bank maturities | Largely done (3Q26 release) |
| FY2026 | Voluntary extension of Argentine local bonds | Liability management | Terms n/d | Launched |
| FY2026 | External strategic assessment of continuing operations | Strategy | Roadmap for portfolio, channels, R&D | Concluded (FY2026 release) |
| FY2026 | Inventory normalization | Working capital | Inventories US$87.6M to US$46.1M; US$4.0M non-recurring obsolescence charge in 4Q26 | Ongoing |
| Sep 2026 | Nasdaq compliance plan | Listing | Notified intent to cure, possibly by reverse split; deadline March 15, 2027 | Pending |
| 2,026 | Potential sale of non-strategic assets | Portfolio | Reported by Forbes Argentina | Unconfirmed |
Guidance and medium-term targets
No quantitative guidance has been provided for FY2027. Management lists qualitative priorities: cash generation, cost and working-capital discipline, and addressing the capital structure. On the 1Q26 call, management said it had operated "well above the gross margin limit" it set for itself, but did not specify the threshold in retrieved text.
Historical targets were missed. The HB4 wheat incremental EBITDA target of US$15–20M for FY2024 (set in FY2022) is no longer relevant after the licensing pivot. The ambition to grow FY2025 EBITDA above FY2024's US$81M was missed: actual FY2025 Adjusted EBITDA was US$28.3M.
ESG and sustainability commitments
The IR site lists a Sustainability Report, Scope 1 & 2 emissions disclosure, Product Environmental Assessments and CSR pages. Quantitative targets are n/d in retrieved sources.
Products & Services
Bioceres does not publish a full SKU-level catalog in its filings. The entries below are drawn from filings, earnings materials and press coverage. Pricing models are not disclosed, beyond the general model of distributor sales plus licensing royalties.
Crop Protection
| Product line | Description / capability | Target customer | Status / year | Notes |
|---|---|---|---|---|
| Adjuvants (Rizobacter) | Spray additives that improve agrochemical efficacy, deposition and drift control | Distributors and growers in Argentina, Brazil, other LatAm | Mature; Brazil adjuvant sales "almost doubling" in 4Q FY2025 per CEO | Adjuvants improved gross profit and margin in 4Q26 despite lower volumes in Brazil |
| Rizoderma | Biological (Trichoderma-based) seed treatment and bio-fungicide | Soybean and wheat growers | Commercial | Named in the 20-F risk factors |
| Bio-protection seed treatments (ex-PFG, U.S.) | Biocontrol seed treatments that drove U.S. growth in FY2024–FY2025 | U.S. row-crop seed companies and growers | Lost with the PFG foreclosure (Jan 2026) | Discontinued operations |
| Third-party crop protection | Resale of generic and branded agrochemicals | Argentine distributors | Deliberately de-emphasized | Faced price competition; lower profitability in 4Q26 |
| Rinotec | Product whose regulatory approval was cited as an FY2025 milestone (Quartr event summary) | — | Approved FY2025 | Specifications n/d |
Seed and Integrated Products
| Product line | Description / capability | Target customer | Status / year | Notes |
|---|---|---|---|---|
| HB4® wheat | Drought-tolerant GM wheat built on a sunflower HaHB4 transcription-factor gene licensed from Bioceres Group | Wheat seed companies (licensees) and growers | Argentina approval 2020/2022; Brazil cultivation approval 2023; U.S. clearance cited FY2024 | Moving from own-channel seed sales to licensing (20-F FY2025); license terminable after the June 2025 change of control |
| HB4® soybean | Drought-tolerant GM soybean | Soybean seed companies and growers | Approved across all soybean-producing countries in the Americas after the Uruguay/Bolivia approvals (late 2024) | Licensing model |
| Seed treatment packs | Integrated packs of biological and chemical seed treatments sold alongside seed | Seed companies and growers | Growing; higher gross profit in 4Q26 | A bright spot in a shrinking segment |
| Grain integration programs (HB4) | Identity-preserved grain programs | Millers and exporters | Being wound down | Low margin; deliberately reduced |
Crop Nutrition
| Product line | Description / capability | Target customer | Status / year | Notes |
|---|---|---|---|---|
| Inoculants | Rhizobia-based biological nitrogen fixation for soybean and other legumes. Rizobacter has claimed leadership in global soybean inoculant market share (Infocampo). | Growers and distributors worldwide | Mature | FY2026 obsolescence adjustment on inoculants; lower contribution from the Syngenta agreement |
| Biological seed treatments supplied to Syngenta | Rizobacter-originated biological seed treatments distributed exclusively by Syngenta outside Argentina | Syngenta (global distribution) | Commercial since about FY2023 | Up-front payment recognized: US$33M in FY2023, about US$17M in FY2024 |
| Micro-beaded / micro-granulated fertilizers | Starter fertilizers produced by Synertech (Pergamino), with three lines marketed in Argentina and LatAm | Corn and soybean growers | Plant operating since 2016 | Main FY2026 growth driver (+36% in 4Q26); pricing pressure in 1Q26 |
| Biostimulants | Plant biostimulants; strong European sales noted in FY2024 (partly PFG-linked) | Growers | Commercial | European biostimulant exposure largely lost with PFG |
| UHC nitrogen-fixation technology | Patented biological nitrogen-fixation platform | Future product pipeline | Patent obtained FY2024 | Commercial status n/d |
Former Pro Farm Group portfolio (discontinued, January 2026)
The former Marrone Bio portfolio was headquartered in the U.S. with European operations. It included the bio-fungicide Regalia, the bio-insecticide Grandevo, the bio-insecticide/nematicide lines Venerate and Majestene, and the Stargus bio-fungicide. These brands left the group with the foreclosure. The company disputes the foreclosure in the New York litigation, so any future recovery or transition arrangement could change this status.
Financial Narrative
Income statement
Sources: FY2022 release (Sept 8, 2022): Adjusted EBITDA US$51.5M; FY2021 Adjusted EBITDA US$48.3M; Baseline Adjusted EBITDA US$61.9M. FY2023 release (Sept 11, 2023). FY2024 release (Sept 9, 2024), plus World-Grain/Cultivar for the FY2023 operating profit of US$54.2M and net income of US$20.2M. FY2025 release (Sept 9, 2025). FY2026 release (Sept 14, 2026).
FY2024 net income was later recast to US$7.3M in the FY2025 release, against US$6.2M originally. FY2025 total comprehensive loss was US$59.6M; FY2026 total comprehensive loss was US$231.4M.
FY2026 continuing EPS of −0.74 is derived as the parent-attributable continuing loss of US$46.9M divided by 63.6M shares. Including the discontinued loss, the derived EPS is about −3.56; the aggregator shows TTM EPS of −3.90.
Internal inconsistency flag. The FY2026 income statement shows a continuing net loss of US$54.4M. The attribution table below it sums to US$50.4M (parent US$46.9M plus NCI US$3.5M). The US$4.0M gap is unexplained in the release; await the FY2026 20-F.
Margins (%)
All margins are computed from reported figures. FY2025 continuing margins use the recast US$289.4M base.
Revenue CAGR. FY2023 to FY2026 (US$419.8M to US$238.3M) is −17.2% a year. This mixes bases: about US$46M of the decline is the PFG deconsolidation, so the organic decline is somewhat smaller. On a continuing basis, FY2025 to FY2026 was −17.7%.
Quarterly profile, FY2026
1Q26 was reported before the PFG reclassification. 2Q26 standalone metrics are n/d in retrieved sources; 2Q26 carried the US$179M non-cash impairment.
Balance sheet
FY2022–FY2024 balance sheet data are n/d in retrieved primary sources.
FY2026 current assets include US$44.4M of "assets subject to foreclosure," and current liabilities include US$29.4M of "liabilities subject to foreclosure." These are residual PFG items. 1Q26 total financial debt was US$242.5M (1Q26 call). The 3Q26 net financial debt of US$212.9M was described as stable versus 2Q26.
Cash flow
FY2025 operating cash flow of US$53.0M was +27% YoY (FY2025 release), which implies FY2024 of about US$41.7M.
FY2026 operating cash flow, capex and FCF are n/d in the earnings release. Management emphasized working-capital release: receivables fell from US$165.9M to US$98.2M and inventories from US$87.6M to US$46.1M. Part of that reduction is the PFG reclassification.
Capex history is n/d. Buybacks: a share repurchase program existed (20-F risk factor references it), but FY2025–FY2026 amounts are n/d. No material repurchases are likely given the liquidity position.
Ratios (computed; FY2025 continuing-basis P&L where applicable)
ROE and ROA for FY2025 need FY2024 balance sheet data, which is n/d. ROIC is n/m: operating income is negative and the invested-capital base is distorted by the foreclosure. The cash conversion cycle is n/d because COGS-based payables and inventory days would be distorted by the PFG reclassification.
On a simple FY2026 basis: receivables of US$98.2M against continuing revenue of US$238.3M is about 150 days; inventory of US$46.1M against COGS of US$155.4M is about 108 days; payables of US$57.6M against COGS is about 135 days. That gives an indicative cycle of roughly 120 days, which is high for the sector and typical of Argentine credit terms.
Commentary on trends, inflections and drivers
FY2022–FY2024: growth phase. Revenue rose from about US$336M to US$464.8M, powered by inoculants, adjuvants, the Marrone merger and HB4 launches. Adjusted EBITDA plateaued at about US$81M in both FY2023 and FY2024. Earnings quality was weaker than the headline: the Syngenta up-front accrual contributed US$33M in FY2023 and about US$17M in FY2024, flattering Crop Nutrition. Net income fell from US$20.2M to US$6.2M as financial costs and amortization rose.
FY2025: break. Revenue fell 28%. Argentine deregulation and disinflation removed farmers' incentive to stock inputs as a currency hedge, and micro-beaded fertilizer demand collapsed. 4Q FY2025 Adjusted EBITDA turned negative (−US$4.5M). The covenant breach (net leverage above 3.75x at March 31, 2025) forced the June 2025 note amendment, with costlier PIK-heavy terms and noteholder board seats. Operating cash flow of US$53.0M was a rare positive, achieved through receivables collection.
FY2026: cost reset amid restructuring. Continuing SG&A fell 24% to US$71.2M (variable −38%, fixed −19%), and total operating expenses fell 20% to US$82.3M. That limited the Adjusted EBITDA decline to −12% against an −18% revenue decline. Interest expense, however, jumped 53% to US$33.5M on PIK accrual and penalty economics, and the accelerated notes drove short-term classification. The PFG foreclosure produced a US$179.4M discontinued loss, which wiped out about 82% of total equity.
Inflection signals. 4Q26 revenue was flat YoY (+1%) and Adjusted EBITDA swung US$10.1M positive. Crop Nutrition grew 36% in the quarter, and adjuvants and seed-treatment packs improved gross profit. Against this, Rizobacter bank debt was reprofiled (long-term borrowings rose from US$38.2M to US$60.0M as short-term borrowings fell from US$119.7M to US$47.3M), which pushes near-term maturities out.
Key watch items. Interest coverage is below 1.0x and cash is only US$11.2M. Any outcome of the noteholder dispute that requires cash settlement of the US$118.6M notes would exceed available liquidity. That is the basis for the going-concern doubt the company itself discloses.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment Overview
| Segment | What it contains | Principal products/services |
|---|---|---|
Crop Protection | Adjuvants, biologicals for pest and disease control, seed-protection products, third-party crop protection resale. Historically also PFG bio-protection (now discontinued). | Proprietary adjuvants (Argentina, Brazil); Rizoderma biological; third-party agrochemicals (Argentina) |
Seed and Integrated Products | HB4 seed and grain programs, seed genetics, seed treatment packs | HB4 wheat and soybean (moving to licensing); integrated seed treatment packs |
Crop Nutrition | Inoculants (biological nitrogen fixation), biostimulants, micro-beaded fertilizers, Syngenta agreement economics | Rizobacter inoculants; micro-beaded fertilizers (Synertech); biological seed treatments supplied to Syngenta |
Revenue by Segment
| Segment (Revenue, USD Mn) | FY2025 | FY2026 |
|---|---|---|
Crop Protection | 147.1 | 123.7 |
Seed and Integrated Products | 63.9 | 37.7 |
Crop Nutrition | 78.5 | 77.0 |
Total Revenue | 289.4 | 238.3 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansSegment (Revenue, USD Mn) Overview
| Segment (Revenue, USD Mn) | FY2025 |
|---|---|
Crop Protection | 181.9 |
Crop Nutrition | 89.5 |
Seed and Integrated Products (derived as total minus other segments) | 63.9 |
Total Revenue | 335.3 |
Revenue by Segment — Crop Protection
| Segment (Gross profit, USD Mn) | FY2025 | FY2026 |
|---|---|---|
Crop Protection | 49.9 | 41.7 |
Seed and Integrated Products | 19.1 | 17.4 |
Crop Nutrition | 36.0 | 23.7 |
Total Gross Profit | 105.0 | 82.9 |
Revenue by Segment (%)
| Segment (Gross margin, %) | FY2025 | FY2026 |
|---|---|---|
Crop Protection | 33.9 | 33.7 |
Seed and Integrated Products | 29.9 | 46.2 |
Crop Nutrition | 45.9 | 30.8 |
Total | 36.3 | 34.8 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansSegment Revenue
| Segment | FY2026 revenue YoY % | FY2026 % of revenue | FY2026 gross profit YoY % |
|---|---|---|---|
Crop Protection | −16 | 51.9 | −16 |
Seed and Integrated Products | −41 | 15.8 | −9 |
Crop Nutrition | −2 | 32.3 | −34 |
Total | −18 | 100.0 | −21 |
Segment (USD Mn) Overview
| Segment (USD Mn) | 1Q26 (reported, incl. PFG) | 3Q26 (continuing) | 4Q26 (continuing) |
|---|---|---|---|
Crop Protection | 39.9 | 24.6 | 27.7 |
Seed and Integrated Products | 12.6 | 3.2 | 4.8 |
Crop Nutrition | 25.1 | 11.6 | 23.5 |
Total | 77.5 | 39.4 | 55.9 |
Group Entities
| Entity | Role | Ownership |
|---|---|---|
Bioceres Crop Solutions Corp. (Cayman) | Listed holding company | Public |
RASA Holding | Holds the Rizobacter stake | 100% (indirect) |
Rizobacter Argentina S.A. | Core operating company (Pergamino): inoculants, adjuvants, fertilizers | 80% via RASA Holding. 29% of BIOX's held shares are subject to a judicial injunction, and a contingent purchase price of US$17.3M is deemed likely payable (20-F FY2025). |
Bioceres Semillas | Seeds / HB4 integrated programs | Subsidiary (details n/d) |
BCS Holding Inc. | Party to the HB4 license | Subsidiary |
Synertech Industrias S.A. | Micro-beaded fertilizer manufacturing | 50/50 JV, Rizobacter / De Sangosse |
Pro Farm Group, Inc. and subsidiaries (U.S., Brazil, Estonia/Finland, Russia) | Former Marrone Bio biologicals | Foreclosed January 2026; disputed; classified as discontinued |
Income Statement and Per-Share Data
| Metric (USD Mn) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue (as reported; FY2026 continuing) | — | 419.8 | 464.8 | 335.3 | 238.3 |
Revenue — continuing-ops basis (ex-PFG) | — | — | — | 289.4 | 238.3 |
Comparable revenue (non-IFRS, ex-IAS 29) | 319.3 | — | — | — | — |
Gross profit (as reported; FY2026 continuing) | — | — | 186.6 | 131.7 | 82.9 |
Gross profit — continuing basis | — | — | — | 105.0 | 82.9 |
Operating income (as reported; FY2026 continuing) | — | 54.2 | 44.8 | -3.7 | -0.2 |
Operating income — continuing basis | — | — | — | 6.6 | -0.2 |
Adjusted EBITDA (company definition) | 51.5 | 81.1 | 81.4 | 28.3 | 25.5 |
Adjusted EBITDA — continuing basis | — | — | — | 28.9 | 25.5 |
Loss before income tax — continuing | — | — | — | -46.5 | -51.0 |
Net income — continuing operations | — | — | — | -49.1 | -54.4 |
Net income — total (as reported) | — | 20.2 | 6.2 | -55.2 | -233.8 |
Loss from discontinued operations (PFG) | — | — | — | -9.7 | -179.4 |
EPS basic, USD (aggregator for FY2022–FY2025; FY2026 derived continuing) | -0.17 | 0.30 | 0.07 | -0.88 | -0.74 |
Dividends per share, USD | 0 | 0 | 0 | 0 | 0 |
Margin Analysis (%)
| Metric (%) | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
Gross margin | — | 40.1 | 39.3 | 34.8 |
Operating margin | 12.9 | 9.6 | -1.1 | -0.1 |
Adjusted EBITDA margin | 19.3 | 17.5 | 8.4 | 10.7 |
Net margin (total) | 4.8 | 1.3 | -16.5 | -98.1 |
Net margin (continuing) | — | — | -17.0 | -22.8 |
Financial Analysis
| Metric (USD Mn) | 1Q26 | 3Q26 | 4Q26 |
|---|---|---|---|
Revenue | 77.5 | 39.4 | 55.9 |
Gross profit | — | 12.7 | 12.7 |
Net income | -7.5 | -10.0 | -31.8 |
Adjusted EBITDA | 13.6 | -0.6 | 0.6 |
Balance Sheet
| Metric (USD Mn) | FY2025 | FY2026 |
|---|---|---|
Total assets | 763.6 | 471.3 |
Cash and cash equivalents | 32.7 | 11.2 |
Other short-term investments | 2.0 | 1.0 |
Secured notes (current) | 102.3 | 118.6 |
Short-term borrowings | 119.7 | 47.3 |
Long-term borrowings | 38.2 | 60.0 |
Total financial debt | 260.2 | 225.9 |
Net financial debt | 225.5 | 213.6 |
Goodwill | 112.2 | 36.1 |
Intangible assets | 181.2 | 82.2 |
Total equity | 295.2 | 64.1 |
Equity attributable to parent | 265.4 | 39.1 |
Non-controlling interest | 29.8 | 25.0 |
Total liabilities | 468.4 | 407.2 |
Working capital (current assets minus current liabilities) | -29.7 | -51.8 |
Trade receivables (current) | 165.9 | 98.2 |
Inventories | 87.6 | 46.1 |
Trade and other payables (current) | 96.4 | 57.6 |
Cash Flow
| Metric (USD Mn) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Operating cash flow | — | — | 41.7 | 53.0 | — |
Free cash flow (aggregator-derived) | — | — | 31.0 | 43.6 | — |
Dividends paid | 0 | 0 | 0 | 0 | 0 |
Key Financials
| Metric (USD Mn) | FY2025 | FY2026 |
|---|---|---|
Interest expense | -21.9 | -33.5 |
Financial commissions | -3.2 | -4.5 |
Fair value, FX and other | -28.0 | -12.9 |
Total financial result | -53.1 | -50.9 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2025 | FY2026 |
|---|---|---|
ROE (total net income / average equity), % | — | -130.1 |
ROA (continuing net income / average assets), % | — | -8.8 |
ROA (total net income / average assets), % | — | -37.9 |
Current ratio, x | 0.91 | 0.81 |
Debt / equity, x | 0.88 | 3.52 |
Net debt / Adjusted EBITDA, x | 7.8 | 8.4 |
Interest coverage (Adjusted EBITDA / interest expense), x | 1.32 | 0.76 |
Asset turnover (revenue / average assets), x | — | 0.39 |
Revenue by Region
| Region (Revenue, USD Mn) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Argentina | 288.2 | 346.8 | 231.6 |
Brazil | 23.7 | 24.2 | 17.7 |
Rest of Latin America | 21.0 | 22.0 | 23.9 |
North America | 30.4 | 27.4 | 30.1 |
EMEA | 22.0 | 21.3 | 7.9 |
Rest of World | 34.1 | 23.2 | 22.2 |
Total (contracts with customers) | 419.4 | 464.8 | 333.3 |
Geographic Revenue
| Region | FY2024 YoY % | FY2025 YoY % | FY2025 share % |
|---|---|---|---|
Argentina | 20.3 | -33.2 | 69.5 |
Brazil | 2.0 | -26.9 | 5.3 |
Rest of Latin America | 4.3 | 8.9 | 7.2 |
North America | -9.9 | 10.0 | 9.0 |
EMEA | -3.2 | -62.9 | 2.4 |
Rest of World | -31.9 | -4.4 | 6.7 |
Share Price & Returns
| Period | Return % | Start price USD |
|---|---|---|
1 month | 4.55 | 0.34 |
3 months | -12.25 | 0.41 |
Year to date (from Dec 31, 2025) | -72.61 | 1.31 |
1 year | -88.43 | 3.10 |
3 years | -96.99 | 11.92 |
5 years | -97.33 | 13.45 |
Since listing (March 15, 2019) | -92.68 | 4.90 |
Valuation Snapshot
| Metric | Value | Basis |
|---|---|---|
Market capitalization (USD Mn) | about 25 | 0.39 × 63.6M |
Enterprise value (USD Mn) | about 264 | Market cap plus net financial debt (213.6) plus NCI (25.0) |
EV / Sales (x) | about 1.1 | FY2026 continuing revenue |
EV / Adjusted EBITDA (x) | about 10.3 | FY2026 Adjusted EBITDA 25.5 |
P / Book (x) | about 0.6 | Parent equity 39.1 |
P / E | n/m | Losses |
Capital Instruments
| Instrument | Amount | Terms | Classification |
|---|---|---|---|
Secured Notes (convertible plus non-convertible) | 118.6 | Convertible: principal US$67.87M at amendment, 15% (5% cash / 10% PIK), maturity Aug 31, 2027. Non-convertible: US$29.08M, 19% (14% cash / 5% PIK), monthly amortization (20-F FY2025). | Current (accelerated; disputed). Balance does not reflect the US$15M credit bid. |
Short-term borrowings | 47.3 | Mainly Argentine bank and working-capital debt | Current |
Long-term borrowings | 60.0 | Includes reprofiled Rizobacter bank debt and local bonds | Non-current |
Lease liabilities | 10.9 | Current 2.1; non-current 8.8 | Mixed |
Total financial debt (excluding leases) | 225.9 | — | — |
Analyst Conclusions
Management guidance
No numeric FY2027 guidance has been given. Management's stated priorities are improving performance and cash generation of continuing businesses, cost and working-capital discipline, and addressing capital structure and liquidity. The external strategic assessment has been concluded and a three-year plan is in development; neither has been published.
Consensus expectations
There is no reliable consensus. Coverage is minimal and targets are stale. Analysts should model scenarios rather than anchor on consensus.
Bull case
-
Operational trough is behind. 4Q26 revenue was flat YoY and Adjusted EBITDA swung US$10.1M positive. With operating expenses now about US$82M a year, even a modest Argentine recovery could lift Adjusted EBITDA toward US$35–40M. That is an illustrative analyst scenario, not company guidance.
-
Litigation leverage. If courts find the US$15M credit bid for about US$194M of assets commercially unreasonable, the note claim could be substantially reduced or offset, collapsing net debt.
-
Optionality. HB4 royalties, Syngenta biologicals and possible asset sales offer non-linear upside against a roughly US$25M equity value.
Bear case
-
Insolvency arithmetic. Interest of US$33.5M exceeds Adjusted EBITDA of US$25.5M, cash is US$11.2M, and US$165.9M of debt is current. Without a settlement or new money, a restructuring that wipes out equity is plausible.
-
IP and partner fragility. The HB4 license is terminable and the licensor is bankrupt. The Syngenta contribution is falling and inoculants carry obsolescence charges. The "platform" may be worth less than its book value.
-
Listing and dilution. A reverse split is likely, delisting is possible after March 2027, and a debt-for-equity outcome would heavily dilute current holders.
Catalysts and monitorables (next 12 months)
| Catalyst | Expected timing | What to watch |
|---|---|---|
| FY2026 Form 20-F | By October 31, 2026 | Auditor opinion and going-concern language, segment and geography data, compensation |
| New York litigation milestones | Ongoing | Rulings on commercial reasonableness and counterclaims; settlement or transition agreement |
| 1Q27 results | About November 2026 | Argentine planting-season demand; Adjusted EBITDA run-rate |
| Reverse split / Nasdaq compliance | Before March 15, 2027 | Ratio, shareholder approval, hearing panel |
| Asset sales | 2026–2027 | Proceeds versus debt |
| HB4 license status | Ongoing | Any termination notice from the licensor or its bankruptcy trustee |
| Rizobacter local bond extension | Ongoing | Participation rate |
| Argentine macro and credit | FY2027 season | Farmer credit, commodity prices, FX |
Analyst verdict
Bioceres Crop Solutions is no longer the growth-biotech story it marketed between 2019 and 2024. It is a leveraged, Argentina-centric specialty-inputs operator whose equity is a residual claim behind a contested creditor position. The operating evidence is mixed but improving at the margin. Continuing gross margins held near 35–40%, SG&A was cut by about a quarter, and the fourth quarter of FY2026 delivered flat revenue and positive Adjusted EBITDA for the first time in a year. Crop Nutrition, especially micro-beaded fertilizers, adjuvants and seed-treatment packs, shows franchise durability in the core Argentine market.
The capital structure overwhelms that progress. Net financial debt of US$213.6M against US$25.5M of Adjusted EBITDA (about 8.4x) is unsustainable while interest expense exceeds EBITDA. US$118.6M of secured notes sit in default under a disputed acceleration, and the noteholders have already taken the Pro Farm platform for a US$15M credit bid. Equity attributable to shareholders has fallen to US$39.1M. The auditor-level going-concern doubt, the Nasdaq deficiency and the bankruptcy of the former parent, which is also the HB4 licensor, add layers of non-operating risk that ordinary fundamental analysis cannot price with confidence.
The outcome distribution is therefore bimodal. A favorable litigation result or negotiated settlement, combined with asset sales and an Argentine credit recovery, could re-rate an equity priced near US$25M against an enterprise generating about US$25–40M of EBITDA. A creditor-led restructuring, which current cash and coverage metrics make at least as likely, would leave little for existing shareholders. For most institutional mandates, BIOX is not investable as a fundamental long. It belongs, if anywhere, in special-situations or distressed books with legal expertise on New York UCC foreclosure law. The key near-term tells are the FY2026 20-F audit opinion, any settlement or court ruling in New York, and the 1Q27 Argentine selling-season print.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure / appointment | Background (disclosed) | Compensation |
|---|---|---|---|---|
Federico Trucco, PhD | CEO and Executive Director | Bioceres group since 2005; CEO since 2011 (about 15 years) | Bioceres LLC President since 2012; Bioceres S.A. board since 2014 (removed December 2025 per press); President of the Argentine Chamber of Biotechnology (2020) | Individual figures n/d (foreign private issuer, aggregate disclosure). Direct ownership about 0.6% (Simply Wall St). |
Ezequiel Simmermacher | Chief Financial Officer | Effective January 5, 2026 | Prior roles n/d in retrieved sources | — |
Alejandro Villafañe | Principal Accounting Officer | Appointed during the CFO vacancy (2025) | — | — |
José Roque | General Counsel | Spoke on the 3Q26 call (2026) | — | — |
Maria Paula Savanti | Head of Investor Relations | Long-standing IR head | — | — |
Enrique López Lecube | Former CFO | CFO since before the 2019 listing; stepped down in 2025 | Left the board June 2025 and the CFO role August 2025 | — |
Board of Directors
| Director | Role | Since | Background |
|---|---|---|---|
Federico Trucco | Executive Director / CEO | 2019 | See above |
Yogesh Mago | Non-executive Director | July 12, 2022 (ex-Marrone Bio board) | Co-founder and President of Operation Water Inc.; advisory board of Girl Rising; BS Finance and International Business, NYU |
Duraiswami ("D") Narain | Non-executive Director | December 29, 2025 | Ex-Vice Chairman, MD and CEO of Bayer CropScience Ltd (India), 2018–2023; Bayer global head of smallholder farming; non-executive director of RiceTec; founding partner of AgVaya; chairs the board of "AIG" (identified as Agriculture Investment Group, a major BIOX holder) and is a non-executive director of Elemental Altus. MBA Kellogg; Chartered Accountant (ICAI). |
Second Q2 FY2026 non-executive appointee | Non-executive Director | Q2 FY2026 | The CEO letter (March 2026) cites two new non-executive directors in 2Q FY2026; the second name was not confirmed in retrieved sources |
Major Shareholders
| Holder | Shares | Stake % | Source / date |
|---|---|---|---|
Agriculture Investment Group (AIG) | about 9.1–9.8M | 14.4–15.4 | Simply Wall St (2026). Insider-type filings show a purchase of about 2.36M shares in October 2025 and sales in February 2026. |
Ospraie Management, LLC | 6,233,590 | 9.82 | Simply Wall St |
Solel Partners LP | 4,579,364 | 7.21 | Simply Wall St |
Fourth Sail Capital LP | 4,331,096 | 6.82 | Simply Wall St |
Bioceres S.A. (in bankruptcy) | 3,189,161 | 5.02 | Simply Wall St; holding down 66% |
Long Focus Capital Management | 829,748 | 1.31 | Simply Wall St |
Mirae Asset Global Investments | 751,530 | 1.18 | Simply Wall St |
Marshall Wace LLP | 595,410 | 0.94 | Simply Wall St |
Jasper Lake Ventures One LLC / Noah Kolatch | 397,000 held; 8,710,707 beneficial including convertible notes | 12.13 (beneficial, as-converted) | Schedule 13D/A (2026) via StockTitan |
Federico Trucco | about 0.37M (implied) | about 0.6 | Simply Wall St |
Competitive Landscape
Competitors by Segment
| Segment | Competitor | Positioning vs. BIOX |
|---|---|---|
Crop Protection (adjuvants, chemicals) | Corteva Agriscience | Global leader in seeds and crop protection; scale and R&D far larger |
Crop Protection | Bayer Crop Science | Global chemical and seed major; strong Argentine channel |
Crop Protection | Syngenta Group | Partner in biologicals, competitor in chemicals |
Crop Protection | BASF Agricultural Solutions | Chemicals, inoculants (legacy Becker Underwood) |
Crop Protection / biologicals | UPL (including NPP natural plant protection) | Generics plus biosolutions; aggressive in LatAm |
Crop Protection | FMC Corporation | Diamides and a biologicals push |
Crop Protection (generics, Argentina) | Local and Chinese-sourced generic formulators | Price competition in third-party products |
Crop Nutrition (inoculants) | Novonesis (ex-Novozymes/Chr. Hansen) | Global microbial leader |
Crop Nutrition (inoculants) | Lallemand Plant Care; Indigo Ag; Pivot Bio (U.S. nitrogen) | Biological nitrogen alternatives |
Crop Nutrition (Brazil biologicals) | Biotrop (Biobest); Koppert | Strong in Brazil biologicals |
Seeds / traits | Grupo Don Mario (GDM), Bayer, Corteva, Syngenta seeds; wheat breeders | HB4 must ride on licensee germplasm |
Distribution / LatAm inputs | Lavoro (Brazil) | Distribution peer, also distressed |
Peer Comparison FY2026
| Company | Fiscal year | Revenue | YoY growth % | EBITDA margin % | R&D % of sales | Source |
|---|---|---|---|---|---|---|
Bioceres Crop Solutions | FY2026 (Jun) | 238.3 | −18 (continuing) | 10.7 (Adjusted) | 4.7 | FY2026 release |
Corteva | FY2025 (Dec) | 17,401 | +3 | 22.1 (operating EBITDA US$3,848M) | n/d here | Corteva 10-K FY2025 |
FMC | FY2025 | — | — | — | — | — |
UPL | FY2026 (Mar) | — | — | — | — | — |
Recent Developments
--



